|
Volumn 16, Issue 10, 2002, Pages 1436-1437
|
Highly active antiretroviral therapy for patients with tuberculosis: The solution or the problem? [6]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABACAVIR;
EFAVIRENZ;
ETHAMBUTOL;
ISONIAZID;
LAMIVUDINE;
LOPINAVIR;
NELFINAVIR;
PREDNISONE;
PYRAZINAMIDE;
RIFABUTIN;
RITONAVIR;
STAVUDINE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
TUBERCULOSTATIC AGENT;
ADULT;
CASE REPORT;
DISEASE COURSE;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LETTER;
LYMPHADENECTOMY;
MALE;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
TUBERCULOSIS;
AIDS RELATED COMPLEX;
DRUG ADMINISTRATION;
PRACTICE GUIDELINE;
ADULT;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
ANTI-HIV AGENTS;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
ANTITUBERCULAR AGENTS;
CASE REPORT;
DRUG ADMINISTRATION SCHEDULE;
HIV INFECTIONS;
HUMAN;
MALE;
PRACTICE GUIDELINES;
TUBERCULOSIS;
HUMANS;
|
EID: 0037024770
PISSN: 02699370
EISSN: None
Source Type: Journal
DOI: 10.1097/00002030-200207050-00023 Document Type: Letter |
Times cited : (5)
|
References (13)
|